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Abstract
Background:  Adeno-associated virus (AAV) vectors are promising tools for gene therapy.
Currently, their potential is limited by difficulties in producing high vector yields with which to
generate transgene protein product. AAV vector production depends in part upon the replication
(Rep) proteins required for viral replication. We tested the hypothesis that mutations in the start
codon and upstream regulatory elements of Rep78/68 in AAV helper plasmids can regulate
recombinant AAV (rAAV) vector production. We further tested whether the resulting rAAV
vector preparation augments the production of the potentially therapeutic transgene, insulin-like
growth factor I (IGF-I).
Results: We constructed a series of AAV helper plasmids containing different Rep78/68 start
codon in combination with different gene regulatory sequences. rAAV vectors carrying the human
IGF-I gene were prepared with these vectors and the vector preparations used to transduce
HT1080 target cells. We found that the substitution of ATG by ACG in the Rep78/68 start codon
in an AAV helper plasmid (pAAV-RC) eliminated Rep78/68 translation, rAAV and IGF-I production.
Replacement of the heterologous sequence upstream of Rep78/68 in pAAV-RC with the AAV2
endogenous p5 promoter restored translational activity to the ACG mutant, and restored rAAV
and IGF-I production. Insertion of the AAV2 p19 promoter sequence into pAAV-RC in front of the
heterologous sequence also enabled ACG to function as a start codon for Rep78/68 translation.
The data further indicate that the function of the AAV helper construct (pAAV-RC), that is in
current widespread use for rAAV production, may be improved by replacement of its AAV2
unrelated heterologous sequence with the native AAV2 p5 promoter.
Conclusion: Taken together, the data demonstrate an interplay between the start codon and
upstream regulatory sequences in the regulation of Rep78/68 and indicate that selective mutations
in Rep78/68 regulatory elements may serve to augment the therapeutic value of rAAV vectors.
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Background
Genetic modification of cells is a promising approach to
generating gene products that have therapeutic potential
[1-3]. The human adeno-associated virus (AAV) has
attracted attention as a vector for gene therapy because it
possesses several favorable characteristics. AAV is capable
of infecting dividing and non-dividing cells in vitro and in
vivo and of infecting cells originating from multiple spe-
cies and tissue types. No human disease has been found
to be associated with AAV infection and the virus has a
low immunogenicity in humans [4]. A further potential
advantage for gene therapy applications is that, in the
absence of a helper virus, wild type (wt) AAV can integrate
into the cellular genome, an event that occurs at high fre-
quency into a defined region on the long arm of human
chromosome 19 [5-7]. This site specificity suggests that
AAV may pose a low risk of insertional mutagenesis while
providing the potential for long-term gene expression.
AAV DNA replication is controlled in part by four overlap-
ping Rep proteins (Rep78, Rep68, Rep52 and Rep40) that
are expressed from a single rep gene. Rep78 and Rep68,
initiating at the p5 promoter, are expressed from
unspliced and spliced transcripts, respectively. Rep52 and
Rep40 are similarly produced from transcripts initiating at
the downstream promoter, p19. Rep52 and Rep40 have
been implicated in AAV single-stranded DNA formation
and gene regulation while the two larger Rep proteins
(Rep78 and Rep68) appear to convey the enzyme func-
tions essential for AAV replication as well as regulation of
viral gene expression. The capsid of the mature AAV virion
is composed of three proteins that are translated from one
transcript of the cap gene [8-10]
Three essential components are used to produce recom-
binant AAV (rAAV) vectors. The first is a transgene expres-
sion cassette flanked by two AAV2 inverted terminal
repeats (ITRs) and constructed in a plasmid. The second is
the AAV helper function of Rep and Cap proteins. The
third is the adenoviral helper function provided by the
products of the adenovirus E2A, E4 and VA genes. There
are two commonly used methods for rAAV production.
One method involves co-transfection into adenovirus-
infected human embryonic kidney 293 (293) cells with
two plasmids, one containing the transgene and the other
providing AAV helper function. The second method
involves co-transfection of 293 cells with three plasmids:
the same two plasmids as noted above and a third plas-
mid that substitutes for the wild type (wt) adenovirus by
providing E2A, E4 and VA adenoviral genes to enable viral
replication. The second method offers the advantage of
avoiding wt adenovirus infection and of yielding rAAV
preparations that are presumed to be free of adenovirus.
Insulin-like growth factor I (IGF-I) is a cell signaling
polypeptide that regulates proliferation and differentia-
tion across a wide spectrum of cell types. Acting by both
endocrine and paracrine/autocrine mechanisms, it plays a
central role in the development and maintenance of mul-
tiple organs and tissues [11]. In this capacity, IGF-I has
potential value in gene therapy. For this reason, it was
selected for the present studies.
The potential of rAAV vectors for human gene therapy has
proved elusive in part because of difficulties in producing
rAAV stock with a high enough titer to be practical for
therapeutic applications [12]. It is possible that Rep78/68
plays a role in determining these yields. An early report
[13] suggested that an ATG-to-ACG mutation of the
Rep78/68 native start codon decreased the Rep78/68
translation and increased rAAV vector production up to
eightfold. The regulatory sequences upstream of Rep78/
68 may also influence rAAV yield. Although these regula-
tory sequences may be presumed to influence Rep78/68
expression, vector production and target cell transgene
expression, their role in these functions has not been elu-
cidated.
The motivation for this study was to improve target cell
IGF-I production by increasing rAAV titers during rAAV
preparation. The AAV Helper-Free System (Stratagene)
was the only commercially available system for rAAV vec-
tor preparation. The plasmid pAAV-RC in the system con-
tains the AAV2 rep  and  cap  genes, coding replication
proteins and viral capsid structural proteins required for
AAV vector production. In wt AAV2, the Rep78/68 is reg-
ulated in cis by the endogenous p5 promoter. The tran-
scription initiation site for Rep78/68 is at nt287 and the
translation start codon for Rep78/68 is the ATG from
nt321 to nt323 (ATG321–323) [9]. Sequence alignment of
pAAV-RC with the AAV2 genome demonstrates that
pAAV-RC contains the sequence of AAV2 genome from
nt310 to nt4530, and the p5 promoter region, including
the transcription initiation site for Rep78/68 in the AAV2
genome, is replaced by a heterologous promoter (Figure
1A and Figure 1B). Although the triplet ATG321–323 is still
present in the sequence of rep gene started from nt310 in
pAAV-RC (Figure 1B), the promoter replacement may
change the transcription intiation site of Rep78/68 and
the 5' untranslated sequence of Rep78/68 transcripts, and
may change the translation start codon for Rep78/68.
We tested the hypothesis that mutations in the start codon
and/or upstream sequences of Rep78/68 could augment
rAAV yield from 293 cells and that the resulting rAAV
preparations would augment IGF-I synthesis from trans-
duced human fibrosarcoma HT1080 cells. We tested this
hypothesis by constructing a series of AAV helper plas-
mids containing an ATG or ACG for the Rep78/68 startVirology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
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Schematic illustration of AAV helper plasmids Figure 1
Schematic illustration of AAV helper plasmids. Plasmids pAAV-RC, pAAV-RC/ΔATG and pAAV-RC/ACG contain an 
AAV2 unrelated heterologous sequence (open boxes) upstream of Rep78/68. pAAV-RC/ΔATG has an ATG deletion at the 
translation start codon of Rep78/68, while pAAV-RC/ACG has an ATG-to-ACG mutation at the start codon. Plasmid pAAV-
RC/p19/ACG contains an extra copy of the 813 bp BamH I fragment of pAAV-RC/ACG. Plasmids pAAV-RC/p5 and pAAV/p5/
ACG contain the AAV2 endogenous p5-promoter upstream of Rep78/68 as in wt AAV2. pAAV-RC/p5/ACG has an ATG-to-
ACG mutation at the translation start codon of Rep78/68. Shaded boxes represent AAV2 p5-promoter, rep and cap genes. An 
eleven nucleotide sequence of the p5-promoter is represented by a small shaded box before ATG or ACG in pAAV-RC, 
pAAV/ΔATG, pAAV/ACG and pAAV-RC/p19/ACG.
E: pAAV-RC/p19/ACG
D: pAAV-RC/ACG
C: pAAV-RC/ΔATG
G: pAAV-RC/p5/ACG
B: pAAV-RC
F: pAAV-RC/p5
A: AAV2
BamH I
Rep
ATG p19
Cap
p40
BamH I BamH I
813 bp
310
Rep
p19 ATG p40
BamH I
p5
Cap ITR ITR
310 191
Rep
ΔATG p19
Cap
p40 310
BamH I BamH I
810 bp
Rep
ACG p19 p40
Cap
310
BamH I BamH I
813 bp
Rep
ACG p19 p40 ACG p19
Cap
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BamH I BamH I
813 bp
Rep
ATG p19 p40
Cap
p5 310 191
BamH I BamH I
866 bp
Rep
ACG p19 p40
Cap
p5 310 191
BamH I BamH I
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codon in combination with the endogenous AAV2 p5
promoter or an AAV2 unrelated heterologous regulatory
sequence. The AAV helper plasmids were compared by co-
transfecting 293 cells with these plasmids and two other
plasmids: pAAV-IGF-I, a plasmid carrying a therapeutic
gene and pHelper, a plasmid providing an adenoviral
helper function. The resulting AAV preparations were used
to transduce HT1080 cells and transgene expression was
assessed by measuring IGF-I production.
We found that selected modifications in the start codon
and the upstream regulatory sequences of Rep78/68 sig-
nificantly augmented the production of IGF-I by increas-
ing rAAV yield.
Results
Effect of the Rep78/68 translation start codon in AAV 
helper plasmid on IGF-I Production
There are several ATG triplets near ATG321–323 in pAAV-RC
that are in the same reading frame as ATG321–323, includ-
ing ATG447–449, ATG591–593 and ATG627–629. To determine
whether the ATG321–323is a start codon for Rep78/68
translation in pAAV-RC and whether any other ATG triplet
in the reading frame after ATG321–323 can serve as a start
codon for Rep78/68 in the absence of ATG321–323, we
deleted ATG312–323 to create pAAV-RC/ΔATG (Figure 1C).
As expected, when rAAV-IGF-I was prepared with the con-
struct pAAV-RC and used to transduce HT1080 cells, the
cells secreted the transgene product, IGF-I, into the culture
medium (Figure 2). In contrast, when the rAAV-IGF-I was
prepared with pAAV-RC/ΔATG and used for transduction,
the HT1080 cells did not produce detectable IGF-I (Figure
2). These results suggest that the ATG321–323 in pAAV-RC is
critical for the expression of Rep78/68, and that the other
in-frame ATG triplets do not substitute for ATG321–323in
providing this function.
To determine the role of the Rep78/68 start codon in the
present system, we mutated the ATG321–323 to ACG in
pAAV-RC to create plasmid pAAV-RC/ACG (Figure 1D).
When this plasmid was used with pAAV-IGF-I and
pHelper to prepare rAAV-IGF-I, the vector preparation
generated no detectable IGF-I when used to transduce
HT1080 cells (Figure 2). These results were comparable to
those obtained by deleting the ATG start codon.
Effect of Rep78/68 upstream regulatory sequences in AAV 
helper plasmid on IGF-I production
In pAAV-RC, there is an AAV2 unrelated heterologous
sequence in front of the start codon ATG321–323 (Figure
1B). We postulated that the native p5 promoter may be
able to regulate Rep78/68 even in the presence of the inac-
tivating ATG-to-ACG mutation. This was tested using
pAAV-RC/p5/ACG (Figure 1G) in which the heterologous
upstream sequence of pAAV-RC/ACG was changed to the
endogenous p5 promoter. rAAV-IGF-I was prepared with
pAAV-RC/p5/ACG and used for transduction. The trans-
duced HT1080 cells produced IGF-I (149.74 ng/ml ±
53.24, N = 4) (Figure 2). This finding indicates that the p5
promoter upstream enables the ACG triplet to function as
a start codon for Rep78/68.
We further postulated that, in the presence of an ATG start
codon, the endogenous p5 promoter sequence augments
Rep78/68 expression in comparison to the heterologous
sequence with an ATG start codon (pAAV-RC) and to the
endogenous p5 promoter with an ACG codon (pAAV-RC/
p5/ACG). This was tested using pAAV-RC/p5 (Figure 1F).
When rAAV-IGF-I was prepared with pAAVRC/p5 and
used for transduction, the transduced HT1080 cells pro-
duced IGF-I (228.04 ng/ml ± 52.37, N = 4) (Figure 2). This
level of IGF-I production was significantly higher than
that generated with pAAV-RC or pAAV-RC/p5/ACG (P <
0.001 and = 0.0044, respectively).
In wt AAV2, the two small Rep proteins (Rep52 and
Rep40) are regulated by a p19 promoter sequence [9]. We
hypothesized that the p19 promoter sequence could also
enable Rep78/68 translation when substituted for the p5
promoter. This hypothesis was tested by inserting an extra
copy of the 813 bp BamH1 fragment (ACG) into pAAV-
RC/ACG to create pAAV-RC/p19/ACG (Figure 1E), con-
taining a p19 promoter sequence upstream of the ATG-to-
ACG mutation. Like pAAV-RC/p5/ACG, this construct led
to IGF-I production by transduced HT1080 cells (58 ng/
ml ± 30.56, N = 4) (Figure 2). The data suggest that the
IGF-I production from HT1080 cells transduced with rAAV- IGF-I preparations made with the designated AAV helper  plasmids Figure 2
IGF-I production from HT1080 cells transduced with 
rAAV-IGF-I preparations made with the designated 
AAV helper plasmids. Data represent the means and SDs 
from four independent experiments.










	







	






ǻ






	












	

















	











	













I
G
F
-
I
 
(
n
g
/
m
l
)Virology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
Page 5 of 11
(page number not for citation purposes)
p19 promoter in the first copy of the 813 bp BamH1 frag-
ment (ACG) enables the ACG triplet in the second copy of
the 813 bp BamH1 fragment (ACG) to function as the
start codon of Rep78/68. Interestingly, a similar construct
of pAAV-RC/p19/ACG, but with the opposite orientation
of the first copy of p19 promoter sequence, was ineffective
and resulted in no IGF-I production (data not shown).
Effect of AAV helper mutations on rAAV titer
The observed differences in IGF-I production by the differ-
ent AAV helper constructs presumably reflects differences
in the assembly of rAAV that transduces the HT1080 target
cells. This presumption was tested by using real time PCR
to quantify the rAAV titer generated by the different AAV
helper constructs.
We found that AAV titers correlated with each prepara-
tion's transduction capacity as reflected in the production
of IGF-I by transduced HT1080 cells. The highest rAAV
titer was obtained when pAAV-RC/p5 was used as the AAV
helper construct (Figure 3). This construct achieved 1.95 ×
1011 packaged genomes/10-cm plate, 2.7 fold higher (p =
0.001, N = 4) than with the starting helper construct,
pAAV-RC. The lowest titer, 1.41 × 109 packaged genomes/
10-cm plate, was obtained with pAAV-RC/ΔATG. This titer
was 51.1 fold lower than that obtained with pAAV-RC
(Figure 3). The other helper constructs generated rAAV tit-
ers intermediate to these values (Figure 3).
These data substantiate the use of IGF-I production as an
index of rAAV titer in the preparations used to transduce
the HT1080 target cells. The failure of vector preparations
derived from pAAV-RC/ΔATG and pAAV-RC/ACG to elicit
IGF-I production suggests that titers below 2.25 × 109
packaged genomes/10 cm plate, as observed with pAAV-
RC/ΔATG (1.41 × 109 packaged genomes/10 cm plate)
and pAAV-RC/ACG (2.25 × 109 packaged genomes/10 cm
plate), is too low to produce detectable IGF-I transgene
product when used to transduce HT1080 cells.
Effect of AAV helper plasmids on Rep78/68 expression 
during rAAV preparation
The effect of these mutations on rAAV yield, and ulti-
mately on IGF-I transgene expression, is presumably
mediated by differential regulation of Rep78/68. To test
this hypothesis, we measured the effect of start codon and
upstream regulatory sequences on the expression of
Rep78/68 protein using western blotting analysis. We
found that protein levels of Rep78 and Rep68 (Figure 4)
were dependent on the construct employed and corre-
lated with rAAV-IGF-I titer (Figure 3) and, in turn, IGF-I
production by transduced HT1080 cells (Figure 2). Bands
corresponding to Rep78 and Rep68 were most intense for
pAAV-RC/p5 and pAV1. In both instances, Rep78 was sev-
eral fold more abundant than Rep68. The Rep78 band
intensity was much lower and Rep68 was barely detecta-
ble for pAAV-RC. The constructs pAAV-RC/p19/ACG and
pAAV/p5/ACG generated a single predominant band
between the positions of Rep78 and Rep68. This shift in
relative molecular mass remains unexplained. No Rep78
or Rep68 expression was observed for either pAAV-RC/
rAAV-IGF-I titers, determined by real-time PCR, of rAAV- IGF-I preparations made with the designated AAV helper  plasmids Figure 3
rAAV-IGF-I titers, determined by real-time PCR, of 
rAAV-IGF-I preparations made with the designated 
AAV helper plasmids. rAAV-IGF-I titers are expressed as 
viral packaged genomes/10-cm plate. Data represent the 
means and SDs from four independent experiments.









	







	






ǻ






	












	

















	











	













r
A
A
V
-
I
G
F
-
I
 
t
i
t
e
r
 
(
E
+
1
1
)
Western blot analysis of Rep protein expression by 293 cells  co-transfected with pAAV-IGF-I, the adenovirus helper plas- mid pHelper and the designated AAV helper plasmids Figure 4
Western blot analysis of Rep protein expression by 
293 cells co-transfected with pAAV-IGF-I, the adeno-
virus helper plasmid pHelper and the designated 
AAV helper plasmids. Plasmid pAAV-RC (lane 1), pAAV-
RC/ΔATG (lane 2), pAAC-RC/ACG (lane 3), pAAV-RC/p19/
ACG (lane 4), pAAV-RC/p5 (lane 5) and pAAV-RC/p5/ACG 
(lane 6). As a control, cells were co-transfected with the ade-
novirus helper plasmid pHelper and pAV1 (lane 7). Two days 
after the co-transfection cells were harvested, lysates were 
separated by SDS-PAGE and Western blotting was per-
formed as described in Materials and Methods.
Rep 78
Rep 68
Rep 52
Rep 40
123 4 567Virology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
Page 6 of 11
(page number not for citation purposes)
ΔATG or pAAV-RC/ACG, consistent with the failure of
these constructs to generate rAAV-IGF-I preparations that
yielded IGF-I. The anti-Rep antibody also identified a high
molecular mass band at Mr ~140 kd that may reflect
Rep78/68 dimerization [14]. The expression levels of the
two small Rep proteins, Rep52 and Rep40 were similar
among all six AAV helper constructs and pAV1 (Figure 4).
These results demonstrate that the deletion of ATG321–323
or the mutation of ATG to ACG in pAAC-RC, abolished
Rep78/68 protein expression. The data further demon-
strate that the p5 promoter or p19 promoter regulatory
sequences upstream were able to partially restore Rep78/
68 production in the presence of this inactivating muta-
tion from ATG to ACG. These findings suggest that the
effects of these mutations on vector yield and resulting
transgene expression are mediated by their effects on
Rep78/68 expression.
Virus yield comparison between rAAV and wt AAV2
To compare the virus yield between rAAV and wt AAV2
when AAV virus are prepared using an adenovirus free
AAV preparation system, two different combinations of
plasmids were used to transfect 293 cells. pAV1 with
pHelper generated a wt AAV yield of 2.29 × 1012 ± 2.01 ×
1011  per packaged genomes/10-cm plate. pAAV-RC/p5
with pHelper and pAAV-IGF-I yielded an rAAV-IGF-I titer
of 1.78 × 1011 ± 2.18 × 1010 per packaged genomes/10-cm
plate, a value that is significantly lower (12.9 fold differ-
ence, P < 0.001, N = 3) than that of wt AAV (Figure 5).
Discussion
Difficulty in generating high titers of rAAV is an ongoing
limitation in the application of rAAV technology to gene
therapy. In the present studies, we investigated the mech-
anisms that regulate the production of rAAV. We found
that the middle base in the start codon for Rep78/68 in
the AAV helper construct plays a key role in this process.
Specifically, the mutation of ATG321–323 of Rep78/68 to
ACG in plasmid pAAV-RC reduced rAAV production to a
degree comparable to that obtained by deleting this
codon. The associated loss of Rep78/68 protein expres-
sion in western blotting studies suggests that this effect is
mediated by a reduction in Rep78/68 translation from
this start codon.
These studies also clarify the role of sequences upstream
of the Rep78/68 start codon in regulating rAAV produc-
tion. Insertion of an AAV2 promoter sequence (p5 pro-
moter) upstream of the ATG start codon in pAAV-RC
increased production of rAAV by 2.7 fold (p = 0.001). This
promoter also converted the otherwise non-functional
ACG-containing construct to one capable of translational
activity.
The regulation of Rep78/68 by upstream sequences can be
subject to modulation by promoters other than the p5
promoter. When the p19 promoter was inserted upstream
of the ACG start codon, translational activity was restored
nearly as effectively as by the p5 promoter. The observed
increase in vector yield suggests that a specific sequence
such as the p5 promoter or p19 promoter upstream of the
ACG is required for the recognition of the codon as a start
codon for translation.
Data from the pAAV-RC/p19/ACG construct also demon-
strate that the orientation of the specific sequences
inserted upstream of the ACG start codon is critical. The
ACG acted as start codon only when the first copy of the
p19 promoter sequence was inserted in the same orienta-
tion as the second copy of p19 promoter sequence (Figure
1E). This suggests that both a specific upstream sequence
such as the p5 promoter or p19 promoter and the specific
sequence orientation are required for ACG to function as
an initiator codon.
Six different AAV helper constructs were tested in this
study. The construct pAAV-RC/p5, containing a p5 pro-
moter upstream and an ATG start codon, achieved the
highest rAAV titer. This titer was 3.4 fold higher (p  =
0.002) than that obtained with pAAV-RC/p5/ACG, indi-
cating that, although the p5 promoter rendered the ACG
codon functional, the ATG codon performed significantly
better in this context. The titer generated by the pAAV-RC/
p5 construct was 2.7 fold higher (p = 0.001) than that
obtained with pAAV-RC, suggesting that the native pro-
Comparison of rAAV-IGF-I and wt AAV2 viral yield Figure 5
Comparison of rAAV-IGF-I and wt AAV2 viral yield. 
Wild type AAV2 was prepared by combining pAV1 (10 μg) 
and pHelper (10 μg) to transfect 293 cells. rAAV-IGF-I was 
prepared by combining the three plasmids: pAAV-RC/p5 (10 
μg), pAAV-IGF-I (10 μg) and pHelper (10 μg) for transfec-
tion. rAAV-IGF-I titer and wt AAV2 titer are expressed as 
viral packaged genomes/10-cm plate. Data represent the 
means and SDs from three independent experiments.
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moter may function more effectively in this application
than the heterologous sequence used in the pAAV-RC con-
struct. Indeed, the AAV helper construct (pAAV-RC) that is
in current widespread use for rAAV production was
improved by the replacement of its AAV2 unrelated heter-
ologous sequence with the native p5 promoter. The mini-
mal difference (5.66 × 1010 versus 3.70 × 1010 packaged
genomes/10-cm plate, P  = 0.344) between the titers
achieved by pAAV-RC/p5/ACG and pAAV-RC/p19/ACG
suggests that the p5 promoter and p19 promoter
sequences are similar in their ability to function as pro-
moters for Rep78/68 when the start codon of Rep78/68 is
changed from ATG to ACG.
In this study, we compared the virus yield of rAAV and wt
AAV2 using the Stratagene Helper-Free System. The titer of
wt AAV2 was 12.9 fold higher (p < 0.001) than that of
rAAV-IGF-I (Figure 5), yet the expression levels of Rep78/
68 in pAV1, and pAAV-RC/p5, were very similar (Figure
4). This large difference in AAV titer in the presence of
similar Rep78/68 expression suggests that factors other
than Rep78/68 expression level are involved in determin-
ing AAV2 virus formation.
In the present studies, a mutation from ATG to ACG in the
start codon decreased Rep78/68 protein. This finding is
consistent with that of Li et al, who compared the two
plasmids pAAV/Ad and pACG-2, containing ATG and
ACG respectively, as Rep78/68 start codons, and noted
that the change of ATG to ACG decreased translation of
the two larger Rep proteins (Rep78 and Rep68) [13]. Of
interest in the present study is the finding that the ATG to
ACG mutation is associated with a decrease in Rep78/68
and a decrease in rAAV titer. This differs in part from an
ATG to ACG associated decrease in Rep that was associ-
ated with an increase in rAAV titer [13]. This difference is
unexplained, but may reflect sensitivity of results to differ-
ences in experimental design or vectors.
The two plasmids, pAAV-RC/p5 and pAAV-RC/p5/ACG,
are identical with the exception that the Rep78/68 start
codon in pAAV-RC/p5 is ATG while in pAAV-RC/p5/ACG
it is ACG. The rAAV yield with pAAV-RC/5 was 3.4 fold
higher (p  = 0.002) than that with pAAV-RC/p5/ACG.
These data indicate that, in the presence of the p5 pro-
moter, the native ATG start codon is more effective than
the mutant ACG start codon.
Initiation of translation by non-AUG codons such as ACG
may be associated with a relatively low expression of the
protein [15]. This was observed in the present studies. As
shown in Figure 4, the levels of Rep78 protein from either
pAVV-RC/p5/ACG or pAAV-RC/p19/ACG are lower than
those from pAV1 or pAAV-RC/p5. During translation,
nucleotides immediately flanking non-AUG codons may
modulate the recognition of non-AUG start codons [15-
17]. This process is unlikely to account for the observed
differences in the Rep78 protein level between pAAV-RC/
ACG and pAAV-RC/p5/ACG in the present study because
the eleven nucleotides immediately upstream of the ACG
in pAAV-RC/ACG and in pAAV-RC/p5/ACG are identical
(Figure 1D and 1G). The present data suggest a similar
role for sequences located more than the eleven nucle-
otides from the ACG codon in pAAV-RC/p5/ACG. The
sequence in the p19 promoter region that similarly ena-
bled ACG function in pAAV-RC/p19/ACG is located at
least 83 nucleotides before the ACG (Figure 1D and 1E).
The titer of rAAV is relevant for gene therapy only if the
rAAV is capable of serving as a vector for a therapeutic
agent. In the present study, we tested the function of these
rAAV vectors by incorporating the human IGF-I gene into
their expression cassette. We found transduction by the
rAAV preparations reliably led to secretion of the trans-
gene protein product in proportion to the rAAV yield.
These data indicate that modifications can be made in the
regulatory regions of AAV helper constructs that improve
rAAV production and do not disrupt transgene expression
or protein product synthesis and secretion.
Taken together, these studies indicate that the regulation
of rAAV production by Rep78/68 is complex. The rAAV
titer is determined not only by the specific upstream regu-
latory sequences and translation start codons in Rep78/
68, but also by specific interactions among these ele-
ments. The IGF-I production data demonstrate that spe-
cific mutations in Rep78/68 regulatory elements may
serve to improve the utility of rAAV vectors for the delivery
of therapeutic transgenes to target cells. Further studies
will be required to optimize the value of rAAV through
this and other mechanisms of rAAV synthesis and action.
Conclusion
Our results demonstrate an interplay between start codon
and upstream regulatory sequences in the regulation of
Rep78/68 translation. Specifically, the p5 or p19 pro-
moter sequence is required for the use of ACG as a start
codon for Rep78/68 translation, suggesting that specific
sequences are required for assisting the initiator tRNA in
recognizing ACG as a start codon. We also found that the
AAV helper construct that is in current widespread use for
rAAV production was improved by the replacement of its
AAV2 unrelated heterologous sequence with the native p5
promoter. Indeed, the native start codon, ATG, combined
with the native p5 promoter, performed best of the six
AAV helper constructs tested in this study. Our data sug-
gest that decreases in the translation of the two larger Rep
proteins (Rep78 and Rep68) decreases rAAV titer. How-
ever, our data also demonstrate a large difference in AAV
titer between rAAV and wt AAV2 (Figure 5) in the presenceVirology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
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of similar Rep 78/68 expression, suggesting that factors
other than Rep 78/68 expression level are also involved in
determining AAV2 virus formation. The data further dem-
onstrate that rAAV vectors derived from these modified
plasmids are effective in generating IGF-I overexpression
in transduced target cells. These findings suggest that
selective mutations in Rep78/68 regulatory elements may
augment rAAV applications in gene therapy.
Methods
pAAV vector construction
Recombinant AAV vectors were prepared using plasmids
pAAV-MCS, pAAV-IRES-hrGFP, pAAV-RC and pHelper
(AAV Helper-Free System, Sratagene, La Jolla, CA). In this
system, AAV2 rep and cap genes are provided by pAAV-RC.
pAAV-IRES was constructed by inserting an internal ribos-
ome entry site (IRES) element into pAAV-MCS at BamH I
and Sal I sites. The IRES element was generated by PCR
using plasmid pAAV-IRES-hrGFP as a template and the
two IRES primers (Table 1): IRESF and IRESR. To facilitate
cloning, a BamH I site and a Sal I site were added to the 5'
end and the 3' end of the PCR product, respectively. The
IRES PCR product was cloned into pCR II-TOPO (Invitro-
gen) to create pCR II-IRES. After sequence confirmation,
the IRES fragment was sub-cloned into pAAV-MCS to
obtain pAAV-IRES.
We then inserted two copies of the cDNA encoding
human IGF-I into pAAV-IRES. One was placed before the
IRES at the EcoR I and BamH I sites and another was
placed after the IRES at the Sal I and Bgl II sites. The first
IGF-I fragment was generated by PCR using pCMVhIGF-I
[18] as a template and primers (Table 1): IGF-IF1 (EcoR I)
and IGF-IR (Bgl II). The second IGF-I fragment was gener-
ated by PCR using the same plasmid as the template and
primers: IGF-IF2 (Sal I) and IGF-IR (Bgl II). The IGF-I PCR
products were cloned into pCR II-TOPO (Invitrogen) and,
after sequence confirmation, were sequentially sub-
cloned into pAAV-IRES to obtain plasmid pAAV-IGF-I-
IRES-IGF-I, abbreviated as pAAV-IGF-I.
Construction of AAV helper plasmids
All AAV helper constructs shown in Figure 1B–G were gen-
erated from pAAV-RC. To facilitate enzymatic manipula-
tion and DNA sequencing, mutagenesis was performed in
vector pCR II. pCRII was created by removing the IRES
from pCR II-IRES with restriction enzyme EcoR I and re-
ligation with T4 ligase. An 813 bp BamH I fragment con-
taining an AAV2 unrelated heterologous sequence and a
part of the rep  gene from nt310 to nt1050 of AAV2
genome including the Rep78/68 start codon (ATG)
(pAAV-RC, Figure 1B), was cut off from pAAV-RC with
restriction enzyme BamH I and cloned into the pCR II vec-
tor to obtain plasmid labeled as pCR II-813. The Rep78/
68 start codon, ATG, was deleted in pCR II-813 by Quik-
Change Site-Directed Mutagenesis (Stratagene) using
primers: RCMDF and RCMDR (Table 1). After sequence
confirmation, the 810 bp fragment (ATG deletion) was
cut out with restriction enzyme BamH I, replacing the
original 813 bp BamH I fragment in pAAV-RC to create
pAAV-RC/ΔATG (Figure 1C). Construction of pAAV-RC/
ACG (Figure 1D), in which the ATG start codon is
changed to ACG, was performed in the vector, pCR II-813
using QuikChange Site-Directed Mutagenesis with prim-
ers: RCMF and RCMR (Table 1). After sequence confirma-
tion, the 813 bp BamH I fragment (ACG) was cut out from
the pCR II vector, replacing the original 813 bp BamH I
Table 1: Primers and probes used for plasmid construction and real-time PCR
IRESF (BamH I)   5'-TCGGATCCAGCAATTCCTCGACGACTGCATAGG-3'
IRESR (Sal I)  5'-GAGTCGACCATGGTTGTGGCCATTATCATCGTG-3'
IGF-IF1 (EcoR I) 5'-CAGAATTCACAATGGGAAAAATCAGCAGTCTTCC-3'
IGF-IF2(Sal I) 5'-ACGTCGACACAATGGGAAAAATCAGCAGTCTTCC-3'
IGF-IR (Bgl II) 5'-CTAGATCTCTACATCCTGTAGTTCTTGTTTCCTG-3'
WF (BamH I) 5'-TCGGATCCGTCCTGTATTAGAGGTCACG-3'
WR (BamH I) 5'-CAGGATCCACTGCTTCTCCGAGGTAATCC-3'
WMF 5'-AACGCGCAGCCGCCACGCCGGGGTTTTACGAG-3'
WMR 5'-TCGTAAAACCCCGGCGTGGCGGCTGCGCGTTC-3'
RCMF 5'-ATCTGCGCAGCCGCCACGCCGGGGTTTTACGAG-3'
RCMR 5'-TCGTAAAACCCCGGCGTGGCGGCTGCGCAGATC-3' 
RCMDF 5'-ATCTGCGCAGCCGCCCCGGGGTTTTACGAGATTG-3' 
RCMDR 5'-TCGTAAAACCCCGGGGCGGCTGCGCAGATCAGAAG-3'
CMVF 5'-TGGGCGGTAGGCGTGTAC-3'
CMVR 5'-CGATCTGACGGTTCACTAAACG-3'
CMV probe 5'-FAM-TGGGAGGTCTATATAAGCAGAG-MGBNFQ-3'
AAV2F 5'-CAGATTGGCTCGAGGACACTCT-3'
AAV2R 5'-GTGGGCCAGGTTTGAGCTT-3'
AAV2 probe 5'-FAM-TGAAGGAATAAGACAGTGGTA-MGBNFQ-3'Virology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
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fragment in pAAV-RC. Construction of pAAV-RC/p19/
ACG (Figure 1E) was performed by inserting two copies of
the 813 bp BamH I fragment (ACG) at BamH I sites to
replace the original 813 bp BamH I fragment in pAAV-RC.
To create a construct containing the ATG start codon and
the p5 promoter regulatory sequence, the BamH I frag-
ment within pAAV-RC/p5 (Figure 1F), which corresponds
to the sequence from nt191 to nt1050 of AAV2 genome
(Figure 1A), was generated by PCR using plasmid pAV1
(American Type Culture Collection, ATCC, Manassas, VA)
[19] as a template and primers: WF and WR (Table 1). An
extra BamH I site was added to the 5' end of the PCR prod-
uct to facilitate cloning. The resulting 886 bp BamH I PCR
product was cloned into the pCR II vector, creating the
plasmid pCR II-866. After sequence confirmation, the 866
bp BamH I fragment was cut out of pCR II-866 and used
to replace the original 813 bp BamH I fragment in pAAV-
RC, creating the construct pAAV-RC/p5. To generate the
construct pAAV-RC/p5/ACG (Figure 1G), the change of
ATG to ACG was performed in pCR II-866 using Quik-
Change Site-Directed Mutagenesis with primers: WMF
and WMR (Table 1). After sequence confirmation, the 866
bp BamH I fragment (ACG) was cut out from the pCR II
vector and used to replace the original 813 bp BamH I
fragment in pAAV-RC.
Cell culture and virus preparation
Human embryonic kidney 293 (293) cells and human
fibrosarcoma HT1080(HT1080) cells were obtained from
the American Type Culture Collection. All cells were cul-
tured in Dulbecco's minimum essential medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and antibiotics of 100 μg/ml
streptomycin and 100 units/ml penicillin (growth
medium) unless otherwise specified.
rAAV vector was prepared by calcium phosphate transfec-
tion according to the manufacturer's instructions. 2 × HBS
(280 mM NaCl, 1.5 mM Na2HPO4 and 50 mM HEPES,
pH 7.1) was prepared, and reagents were purchased from
Sigma. Briefly, 293 cells were cultured in 10-cm cell cul-
ture plates in growth medium without antibiotics. After 2
days of culture, cells were co-transfected using 10 μg plas-
mid pAAV-IGF-I, 10 μg pHelper and 10 μg of one of the
six AAV helper plasmids (Figure 1B–G). The plasmid
DNAs were added in 1 ml of 0.3 M CaCl2. The DNA/CaCl2
mixture was rapidly mixed with 1 ml 2 × HBS and added
drop-wise to the cells. For wt AAV2 preparation using the
AAV helper-free system, 10 μg plasmid pAV1 and 10 μg
pHelper in 0.67 ml of 0.3 M CaCl2 mixed with 0.67 ml 2
× HBS were used to co-transfect 293 cells. After incubation
for 6 hr at 37°C, the co-transfection was stopped by
replacing the media with 15 ml of growth medium. After
an additional 3 days of culture, the medium was collected
and stored at -80°C prior to IGF-I analysis to assess the co-
transfection efficiency of each of the six constructs. The
transfected cells were collected in DMEM with 2% FBS
and subjected to two freeze/thaw cycles by alternating the
sample between a dry ice-ethanol bath and a 37°C water
bath. Cell debris was removed by centrifugation and the
rAAV preparation was aliquoted and stored at -80°C until
use.
Titration of rAAV-IGF-I vector
The titers of recombinant AAV-IGF-I (rAAV-IGF-I) and wt
AAV2 were determined by real-time PCR using Prism
7000 Sequence Detector System and TaqMan Universal
Master Mix (Applied Biosystems, Foster City, CA) as pre-
viously described [20]. The primers (CMVF and CMVR)
and probe (CMV probe), shown in Table 1, were designed
to target the CMV promoter sequence for rAAV-IGF-I titer
determination. The primers (AAV2F and AAV2R) and
probe (AAV2 probe) in Table 1 were designed to target
AAV2 cap sequence for wt AAV2 titer determination. The
probes were 5'-end FAM and 3'-end MGB non-fluorescent
quencher (MGBNFQ) labeled and custom synthesized
(Applied Biosystem, Foster City, CA). Plasmid pAAV-IGF-
I and pAV1 were used as the standard for quantifying
rAAV-IGF-I and wt AAV2 viral titer in real-time PCR,
respectively.
Transduction of AAV-IGF-I to HT1080 cells
HT1080 cells were transduced with each rAAV-IGF-I prep-
aration according to the AAV Helper-Free System (Strata-
gene) manufacturer's specifications. Briefly, HT1080 cells
at a density of 8 × 104 per well were plated in 1 ml of
growth medium in 24-well tissue culture plates just one
day before transduction. After incubation overnight, 0.5
ml of the growth medium was removed from each well
and 0.5 ml of AAV permissive medium (growth medium
supplemented with 80 mM hydroxyurea and 2 mM
sodium butyrate) was added to each well. The plates were
returned to 37°C incubator. After the 6 hour treatment,
the medium was removed and the cells were washed once
with 1 ml of DMEM with 2% FBS and removed again. The
cells were transduced by adding 125 μl of rAAV-IGF-I and
125 μl of DMEM with 2% FBS to each well. After 2 hour
incubation, 750 μl of growth medium was added to each
well and the cells were cultured overnight. To avoid inter-
ference from IGF-I present in the rAAV preparations, the
medium was removed after transduction and the cells
were washed with growth medium, then 1 ml of fresh
growth medium was added to each well, and the cells
were further cultured for two days.
IGF-I analysis
IGF-I in the conditioned culture medium of the trans-
fected 293 cells, in rAAV-IGF-I preparations and the con-
ditioned medium of the rAAV-IGF-I transduced HT1080Virology Journal 2009, 6:3 http://www.virologyj.com/content/6/1/3
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cells was analyzed with the DuoSet ELISA Development
Kit (R&D Systems, Minneapolis, MN).
Western blotting analyses of AAV Rep proteins
Western blotting analysis of Rep proteins was performed
to assess Rep protein expression following transfection
using the different AAV helper constructs shown in Figure
1. Besides the six AAV helper constructs, the plasmid
pAV1, which contains the full length AAV2 genome, was
included for comparison. 293 cells were co-transfected
with each of AAV helper plasmids mixed with plasmid
pAAV-IGF-I and the adenoviral helper plasmid, pHelper.
The cells were lysed and harvested two days after co-trans-
fection. The samples were separated by SDS-PAGE and
transferred to a nitrocellulose membrane. After blocking
in tris buffered saline with 0.1% Tween-20 and 5% fat free
milk at room temperature for two hours, the blot was
incubated at 4°C overnight with an anti-Rep monoclonal
antibody which recognizes all four Rep protein isoforms
(clone 303.9, American Research Product, Belmont, MA).
Statistical analysis
To compare rAAV-IGF-I yield produced with different AAV
helper plasmids shown in Figure 1B–D, four independent
co-transfection experiments were conducted for rAAV-
IGF-I preparations and each co-transfection was per-
formed in triplicate. To assess the IGF-I production from
the HT1080 cells, four independent transductions were
performed on HT1080 cells using each of the rAAV-IGF-I
preparations. To compare the yield of rAAV-IGF-I made
with pAAV-RC/p5 and pHelper plus pAAV-IGF-I to the
yield of wt-AAV2 made with pAV2 and pHelper, three
independent co-transfections were conducted and each
co-transfection was performed in triplicate. Statistical
analysis was performed using StatView software version
5.1 (SAS Institute, Cary, NC). Data are presented as mean
± standard deviation. The Fisher's PLSD method was used
to assess differences in IGF-I production by transduced
HT1080 cells and differences in rAAV-IGF-I AAV virus titer
between AAV helper constructs. A student's t-Test was
used to assess the difference in AAV virus titer between wt
AAV2 and rAAV-IGF-I made with plasmid pAV1 and
pAAV-RC/p5, respectively. P values less than 0.05 were
considered to represent statistically significant differences.
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